▲ 0.00%
prev close
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
-2
0 buys · 2 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-10-31 | ROIVRoivant Sciences Ltd. - Common Shares | Sell | $1,001 - $15,000 | 194d ago | — | |
| 2025-10-30 | ROIVRoivant Sciences Ltd. - Common Shares | Sell | $1,001 - $15,000 | 194d ago | — |
2025-10-31
Lisa McClain
ROIV
Amount
$1,001 - $15,000
Filed
194d ago
2025-10-30
Lisa McClain
ROIV
Amount
$1,001 - $15,000
Filed
194d ago
Recent News
Powered by Polygon.io
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-10-31 · Sale
$1,001 - $15,000
Lisa McClain
2025-10-30 · Sale
$1,001 - $15,000